Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.
Marianna Fontana, MD, PhD
Advertisement
Marianna Fontana is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London.
Articles by Marianna Fontana, MD, PhD
Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.
Advertisement
Latest Updated Articles
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CMNovember 18th 2024
- Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial
November 20th 2024
Advertisement
Advertisement
Trending on HCPLive
1
Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD
2
6 Gastroenterology Headlines You Missed in May 2026
3
Q&A: How Lifelong Burdens Are Shaped by Childhood Eczema, With Delphine Kerob, MD
4
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
5